Aclaris Historical Financial Ratios
ACRS Stock | USD 3.99 0.19 5.00% |
Aclaris Therapeutics is presently reporting on over 111 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.67 or Days Sales Outstanding of 3.31 will help investors to properly organize and evaluate Aclaris Therapeutics financial condition quickly.
Aclaris |
About Aclaris Financial Ratios Analysis
Aclaris TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Aclaris Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Aclaris financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Aclaris Therapeutics history.
Aclaris Therapeutics Financial Ratios Chart
Add Fundamental
Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Aclaris Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Aclaris Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.At this time, Aclaris Therapeutics' PTB Ratio is comparatively stable compared to the past year. PB Ratio is likely to gain to 0.67 in 2024, whereas Days Sales Outstanding is likely to drop 3.31 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Net Debt To EBITDA | 0.41 | 0.53 | 0.34 | 0.32 | Intangibles To Total Assets | 0.0281 | 0.0274 | 0.001363 | 0.001295 |
Aclaris Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Aclaris Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aclaris Therapeutics fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 18.48 | 42.46 | 122.0 | 34.52 | 2.35 | 2.23 | |
Ptb Ratio | 1.12 | 7.31 | 4.18 | 5.2 | 0.47 | 0.67 | |
Days Sales Outstanding | 60.79 | 43.47 | 33.63 | 5.94 | 3.48 | 3.31 | |
Book Value Per Share | 1.69 | 0.89 | 3.48 | 3.03 | 2.25 | 2.14 | |
Free Cash Flow Yield | (1.26) | (0.14) | (0.0636) | (0.0664) | (1.09) | (1.03) | |
Operating Cash Flow Per Share | (2.33) | (0.91) | (0.92) | (1.04) | (1.12) | (1.18) | |
Stock Based Compensation To Revenue | 3.83 | 1.73 | 2.08 | 0.51 | 0.66 | 0.62 | |
Capex To Depreciation | 0.25 | 0.34 | 0.33 | 0.76 | 1.52 | 1.44 | |
Pb Ratio | 1.12 | 7.31 | 4.18 | 5.2 | 0.47 | 0.67 | |
Ev To Sales | 10.13 | 35.85 | 118.06 | 33.02 | 1.08 | 1.03 | |
Free Cash Flow Per Share | (3.1) | (2.37) | (0.92) | (1.05) | (1.14) | (1.2) | |
Roic | (1.98) | (1.04) | (0.42) | (0.44) | (0.62) | (0.65) | |
Inventory Turnover | 8.66 | 0.82 | (0.14) | (0.98) | (1.12) | (1.07) | |
Net Income Per Share | (3.46) | (1.2) | (2.01) | (1.36) | (1.27) | (1.33) | |
Days Of Inventory On Hand | 42.15 | 447.0 | (2.7K) | (373.61) | (336.25) | (353.06) | |
Payables Turnover | 0.41 | 0.98 | 0.47 | 1.16 | 2.04 | 2.14 | |
Sales General And Administrative To Revenue | 6.42 | 3.17 | 3.49 | 0.84 | 1.0 | 0.95 | |
Research And Ddevelopement To Revenue | 15.35 | 4.9 | 6.48 | 2.62 | 3.15 | 2.99 | |
Capex To Revenue | 0.38 | 0.0699 | 0.0456 | 0.0203 | 0.0419 | 0.0398 | |
Cash Per Share | 1.82 | 2.03 | 3.37 | 3.34 | 1.71 | 1.62 | |
Pocfratio | (0.81) | (7.12) | (15.82) | (15.2) | (0.94) | (0.98) | |
Capex To Operating Cash Flow | (0.0135) | (0.0167) | (0.0117) | (0.005908) | (0.008954) | (0.0175) | |
Pfcf Ratio | (0.8) | (7.04) | (15.73) | (15.07) | (0.92) | (0.97) | |
Days Payables Outstanding | 892.65 | 373.6 | 773.29 | 315.9 | 179.22 | 170.26 | |
Roe | (2.04) | (1.36) | (0.58) | (0.45) | (0.56) | (0.59) | |
Ev To Operating Cash Flow | (0.44) | (6.01) | (15.31) | (14.54) | (0.43) | (0.45) | |
Pe Ratio | (0.55) | (5.38) | (7.22) | (11.58) | (0.83) | (0.87) | |
Return On Tangible Assets | (0.72) | (1.57) | (0.8) | (0.47) | (0.36) | (0.45) | |
Ev To Free Cash Flow | (0.44) | (5.94) | (15.22) | (14.41) | (0.43) | (0.45) | |
Earnings Yield | (1.83) | (0.19) | (0.14) | (0.0863) | (1.21) | (1.15) | |
Intangibles To Total Assets | 0.0732 | 0.1 | 0.0281 | 0.0274 | 0.001363 | 0.001295 | |
Net Debt To E B I T D A | 0.39 | 0.89 | 0.41 | 0.53 | 0.34 | 0.32 | |
Current Ratio | 3.74 | 3.87 | 8.94 | 10.55 | 4.16 | 3.95 | |
Tangible Book Value Per Share | 1.52 | 0.72 | 3.35 | 2.92 | 2.25 | 4.19 | |
Receivables Turnover | 6.0 | 8.4 | 10.85 | 61.47 | 104.86 | 110.11 | |
Graham Number | 11.47 | 4.89 | 12.56 | 9.63 | 8.01 | 15.48 | |
Shareholders Equity Per Share | 1.69 | 0.89 | 3.48 | 3.03 | 2.25 | 2.14 | |
Debt To Equity | 0.009111 | 0.3 | 0.003512 | 0.003461 | 0.00271 | 0.002575 | |
Capex Per Share | 0.039 | 0.0106 | 0.005429 | 0.009277 | 0.0188 | 0.0331 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.